| Company Name: |
3B Pharmachem (Wuhan) International Co.,Ltd.
|
| Tel: |
821-50328103-801 18930552037 |
| Email: |
3bsc@sina.com |
| Products Intro: |
Product Name:D-CPP-ene;D-4-[(2E)-3-Phosphono-2-propenyl]-2-piperazinecarboxylicacid
CAS:117414-74-1
Purity:99% HPLC Package:1Mg ; 5Mg;10Mg ;100Mg;250Mg ;500Mg ;1g;2.5g ;5g ;10g
|
| Company Name: |
Synchem OHG
|
| Tel: |
+49 5662 408730 |
| Email: |
info@synchem.de |
| Products Intro: |
Product Name:D-CPP-ene;Midafotel
CAS:117414-74-1
|
|
| | D-4-[(2E)-3-PHOSPHONO-2-PROPENYL]-2-PIPERAZINECARBOXYLIC ACID Basic information |
| Product Name: | D-4-[(2E)-3-PHOSPHONO-2-PROPENYL]-2-PIPERAZINECARBOXYLIC ACID | | Synonyms: | (R,E)-4-(3-PHOSPHONOPROP-2-ENYL)PIPERAZINE-2-CARBOXYLIC ACID;D-CPP-ENE;D-4-[(2E)-3-PHOSPHONO-2-PROPENYL]-2-PIPERAZINECARBOXYLIC ACID;(2R)-4-[(E)-3-Phosphono-2-propenyl]piperazine-2β-carboxylic acid;Midafotel;2-Piperazinecarboxylic acid, 4-[(2E)-3-phosphono-2-propenyl]-, (2R)-;DCPPene,D CPP ene;(R)-CPPene (SDZ EAA 494) | | CAS: | 117414-74-1 | | MF: | C8H15N2O5P | | MW: | 250.19 | | EINECS: | | | Product Categories: | | | Mol File: | 117414-74-1.mol | ![D-4-[(2E)-3-PHOSPHONO-2-PROPENYL]-2-PIPERAZINECARBOXYLIC ACID Structure](CAS/GIF/117414-74-1.gif) |
| | D-4-[(2E)-3-PHOSPHONO-2-PROPENYL]-2-PIPERAZINECARBOXYLIC ACID Chemical Properties |
| Boiling point | 555.6±60.0 °C(Predicted) | | density | 1.449±0.06 g/cm3(Predicted) | | storage temp. | Desiccate at RT | | form | Powder | | pka | 1.27±0.10(Predicted) | | color | White | | Water Solubility | Soluble to 100 mM in water |
| | D-4-[(2E)-3-PHOSPHONO-2-PROPENYL]-2-PIPERAZINECARBOXYLIC ACID Usage And Synthesis |
| Uses | D-CPP-ene is a potent, competitive NMDA antagonist (1). NMDA antagonists such as this may increase sucrose intake through hunger satiation delay (2). | | Definition | ChEBI: Midafotel is a member of the class of piperazines that is piperazine substituted by a carboxy group at position 2R and a (1E)-1-phosphonoprop-1-en-3-yl group at position 4. It is an antagonist of N-methyl-D-aspartate receptors (NMDARs) and was in clinical development by Novartis for the treatment of cognition disorders and brain injuries (now discontinued). It has a role as a NMDA receptor antagonist, a neuroprotective agent and an anticonvulsant. It is a piperazinecarboxylic acid, a monocarboxylic acid, a member of phosphonic acids, an olefinic compound and a tertiary amino compound. | | Biological Activity | Potent and competitive NMDA antagonist (K i = 40 nM). Centrally active following systemic administration. | | storage | Room temperature |
| | D-4-[(2E)-3-PHOSPHONO-2-PROPENYL]-2-PIPERAZINECARBOXYLIC ACID Preparation Products And Raw materials |
|